Circulating PRCP in STEMI Patients Undergoing Primary PCI
1 other identifier
observational
275
1 country
4
Brief Summary
Purpose: The purpose of this study is to evaluate the impact of acute ST-segment elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (PCI) on circulating prolylcarboxypeptidase (PRCP) level and activity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2016
Shorter than P25 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2016
CompletedFirst Submitted
Initial submission to the registry
May 9, 2016
CompletedFirst Posted
Study publicly available on registry
May 13, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedJanuary 3, 2020
December 1, 2019
2 months
May 9, 2016
December 31, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
Circulating PRCP level
1 month
Circulating PRCP activity
1 month
Secondary Outcomes (4)
Circulating Ang II level
1 month
Circulating Ang-(1-7) level
1 month
Circulating BK-(1-9) level
1 month
Circulating KBK-(1-9) level
1 month
Study Arms (3)
STEMI patients
Healthy subjects
Unstable angina
Interventions
Eligibility Criteria
Healthy subjects, consecutive patients with unstable angina, and those undergoing primary PCI for STEMI
You may qualify if:
- Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes;
- Age ≥18 years;
- Informed consent from subject or next of kin.
You may not qualify if:
- Nonischaemic Cardiomyopathy;
- Cardiac surgery planed in the 6 months;
- Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation);
- Renal or hepatic failure;
- Malignancy, HIV, or central nervous system disorder;
- Cardiopulmonary resuscitation \>15 min and compromised level of consciousness;
- Cardiogenic shock;
- Current participation in any research study involving investigational drugs or devices;
- No written consensus;
- Previous myocardial infarction.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Qianfoshan Hospital, Shandong University
Jinan, Shandong, 250012, China
Shandong University Qilu Hospital
Jinan, Shandong, 250012, China
Jinan Central Hospital, Shandong University
Jinan, Shandong, 250013, China
Shandong Provincial Hospital, Shandong University
Jinan, Shandong, 250021, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
May 9, 2016
First Posted
May 13, 2016
Study Start
May 1, 2016
Primary Completion
July 1, 2016
Study Completion
July 1, 2016
Last Updated
January 3, 2020
Record last verified: 2019-12